EOM Pharmaceuticals Holdings, Inc. (IMUC)

IMUC Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2021	FY 2020
Period Ending	Sep 30, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	1.59	1.31	1.01
Research & Development	0.98	1.3	0.93
Operating Expenses	2.57	2.61	1.94
Operating Income	-2.57	-2.61	-1.94
Interest Expense	-0.13	-0.03	-
Interest & Investment Income	0.14	0.02	-
EBT Excluding Unusual Items	-2.6	-2.62	-1.94
Other Unusual Items	-2.53	-2.53	-
Pretax Income	-5.13	-5.15	-1.94
Net Income	-5.13	-5.15	-1.94
Net Income to Common	-5.13	-5.15	-1.94
Shares Outstanding (Basic)	99	48	45
Shares Outstanding (Diluted)	99	48	45
Shares Change (YoY)	118.93%	5.46%	-
EPS (Basic)	-0.05	-0.11	-0.04
EPS (Diluted)	-0.05	-0.11	-0.04
EBIT	-2.57	-2.61	-1.94

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2022

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 18, 2026

Data Sources Report a data error